Key Points – Solid first-half performance: AstraZeneca reported revenue growth of 6% at constant exchange rates and 11% excluding generic-competition effects, while core EPS rose 11%.
The company maintained its full-year outlook and reaffirmed its goal of reaching $80 billion in revenue by 2030. – Oncology remained the main growth driver: Oncology revenue increased 15% to $14.1 billion, led by CALQUENCE, Enhertu and Imfinzi
AstraZeneca also reported positive Phase III results for soniV in advanced gastric cancer and Imfinzi plus enfortumab vedotin in bladder cancer. – Pipeline progress comes with mixed results: The company began Phase III trials for obesity and diabetes drug candidate elecoglipron after positive Phase IIb data, but Wainua failed to meet its Phase III cardiovascular endpoint. Biopharmaceutical revenue declined 5% as Farxiga and other products faced generic competition, while rare-disease revenue grew 11%. – The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Astrazeneca (NYSE:AZN) reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per share increased 11%. The company reiterated its full-year outlook and said it remains confident in its goal of reaching $80 billion in revenue by 2030.
Chief Executive Officer Pascal Soriot said the first-half performance reflected demand for the company’s innovative medicines and the breadth of its portfolio across oncology, biopharmaceuticals and rare disease. AstraZeneca recorded positive results from six key Phase III programs during the period, including three new molecular entities, and received 30 major-market approvals. – As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade The company’s overall revenue growth was supported by oncology and rare disease, which both posted double-digit growth.